|Ticker||Company name||Industry||Market Cap
|Dividend Yield||Dividend Frequency||Stock price||Currency||Stock Exchange|
|NOVO-B||Novo Nordisk AS||Healthcare||994.68||2.01 %||Semi-Annual||414.45||DKK||NASDAQ OMX Copenhagen|
Company's Past Performance
The 5 years average P/E ratio is the average of each year’s P/E ratios. P/E ratio in any year is limited to 30 in order to reduce the effect of the extreme values on the average P/E.
Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. It offers a range of diabetes product, including new generation insulins and a portfolio of modern insulin. It provides Saxenda, which is a product to treat obesity and is available in Denmark, Italy and Canada. Its other products/compounds include Xultophy, Semaglutide (NN9535), Faster-acting insulin aspart (NN1218), N9-GP (NN7999), N8-GP (NN7088) and NN8640 Once-weekly human growth hormone.
|Company name||Ticker||Share price||Dividend yield|
|Roche Holding AG||ROG||300.25||3%|